Adjuvant nivolumab after pre-operative chemoradiation therapy in esophageal cancer: a clinical case and review of literature of soft-tissue metastases recurrence managed by dose escalation radiotherapy
Abstract
Soft tissue metastasis in esophageal cancer is a very rare entity. A 76-year-old man was referred for a week’s history of dysphagia. Upper gastrointestinal endoscopy was performed, and biopsies were consistent with an adenocarcinoma of the lower esophagus. The patient was free of metastasis on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). The patient was treated with pre-operative chemoradiation, followed by surgery. Intravenous carboplatin [area under the curve of 2 mg/mL/min (AUC2)] and intravenous paclitaxel 50 mg/m2 with concurrent radiotherapy (RT) (45 Gy delivered in 25 fractions of 1.8 Gy per fraction) were introduced from May 31st, 2021, to July 2nd, 2021. Lewis-Santy subtotal esophagectomy was performed, and pathology revealed a ypT3 ypN0 (0/26) L0 V1 Pn1 G3 R0. Adjuvant nivolumab was introduced for a total of 12 months. After five months of nivolumab, the patient complained of a painful left shoulder subcutaneous tumefaction in routine evaluation. Biopsy of the deltoid muscle demonstrated a poorly differentiated adenocarcinoma consistent with esophageal metastasis. Additional skeletal muscle (one) and bone metastases (two) were revealed on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). After multidisciplinary team approach, palliative radiation therapy to all metastases, denosumab and FOLFOX were introduced. Despite initial excellent clinical outcomes, patient presented avascular necrosis of left femoral head managed by surgery but died after post-operative complications. To the best of our knowledge, it is the first reported case with rare soft-tissue metastasis occurring during adjuvant nivolumab in esophageal cancer.
Keywords: oesophageal cancerradiotherapymetastases
References
- El Abiad JM, Hales RK, Levin AS, et al. Soft-Tissue Metastases From Esophageal Cancer. J Gastrointest Surg. 2019; 23(9): 1721–1728.
- Fujimoto Y, Nakashima Y, Sasaki S, et al. Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review. Anticancer Res. 2017; 37(10): 5687–5691.
- Geng X, Liu J, Sun H, et al. Subcutaneous soft tissue metastases from esophageal squamous cell carcinoma with neuroendocrine differentiation: Case report and literature review. Front Oncol. 2022; 12: 895189.
- Xi M, Yang Y, Zhang Li, et al. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes. Ann Surg. 2019; 269(4): 663–670.
- Barbetta A, Sihag S, Nobel T, et al. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery. J Thorac Cardiovasc Surg. 2019; 157(3): 1249–1259.e5.
- Oppedijk V, van der Gaast A, van Lanschot JJB, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014; 32(5): 385–391.
- Kelly RJ, Ajani JA, Kuzdzal J, et al. CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021; 384(13): 1191–1203.
- Zhang RY, Zhu SJ, Xue P, et al. Cutaneous metastasis from esophageal squamous cell carcinoma: A case report. World J Clin Cases. 2022; 10(14): 4676–4683.
- Smyth S, O'Donnell ME, Kumar S, et al. Atypical presentation of an oesophageal carcinoma with metastases to the left buttock: a case report. Cases J. 2009; 2: 6691.
- Puri S, Holle LM, Forouhar FA, et al. Subcutaneous metastasis from recurrent basaloid squamous cell carcinoma of the esophagus. J Oncol Pharm Pract. 2019; 25(2): 492–496.
- Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1): e18–e28.
- Plaza JA, Perez-Montiel D, Mayerson J, et al. Metastases to soft tissue: a review of 118 cases over a 30-year period. Cancer. 2008; 112(1): 193–203.
- Altorki NK, Markowitz GJ, Gao D, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019; 19(1): 9–31.
- Maia A, Schöllhorn A, Schuhmacher J, et al. CAF-immune cell crosstalk and its impact in immunotherapy. Semin Immunopathol. 2023; 45(2): 203–214.